MELT-300 Demonstrates Statistically Superior Compared to Both Sublingual Midazolam (P=0.009) and Placebo (P0.001) for Providing Successful Procedural Sedation Proportion of Patients Requiring Rescue Sedation Was Nearly Two-Fold Higher for Sublingual Midazolam Compared with MELT-300 (P=0.003)

Topline Readout Expected in Q4 2024 FDA Agrees to a MELT-300 Phase 3 Special Protocol Assessment NASHVILLE, Tenn. --(BUSINESS WIRE)--Oct. 10, 2024--  Melt Pharmaceuticals, Inc. (“Melt”), a clinical-stage pharmaceutical company developing novel approaches for procedural sedation, today announced the

Topline Readout Expected in Q4 2024 NASHVILLE, Tenn. --(BUSINESS WIRE)--Jun. 6, 2024-- Melt Pharmaceuticals, Inc. (“Melt”), a clinical-stage pharmaceutical company developing novel approaches for procedural sedation, today announced that the first patient has been dosed in its Phase 3 program

MELT-300 Pivotal Phase 3 Program Topline Readout Expected in Q4 2024 NASHVILLE, Tenn. --(BUSINESS WIRE)--Apr. 2, 2024-- Melt Pharmaceuticals, Inc. (“Melt”), a clinical‑stage pharmaceutical company developing novel approaches for procedural sedation, today announced the completion of its Series B

NASHVILLE, Tenn. --(BUSINESS WIRE)--Jan. 3, 2024-- Melt Pharmaceuticals, Inc. (“Melt”), a clinical‑stage pharmaceutical company developing novel approaches for procedural sedation, today provided a corporate update. The Company previously announced that MELT-300 achieved the primary sedation